DoxyDOT Study

Phase 4

• Conditions: Sexually Transmitted Infections

• Registration Number: PACTR202401619811584
• Lead Sponsor: niversity of Washington

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2024-01-18
• Last Update Posted: 4 March 2024

Recruitment & Eligibility

• Status: Pending
• Sex: Female
• Target Recruitment: 60

Inclusion Criteria

1)Willing and able to give written informed consent
2)Age 18-30 years
3)Female sex at birth
4)HIV-seronegative, according to national HIV testing algorithm
5)Has a current prescription for PrEP, according to the national guidelines of Kenya
6)Able and willing to adhere to DOT dosing schedules

Exclusion Criteria

1)Pregnant
2)Breastfeeding a child
3)Allergy to tetracycline class
4)Current medications which may impact doxycycline metabolism or that are contraindicated with doxycycline, as per the prescribing information. These include systemic retinoids, barbiturates, carbamazepine, phenytoin, and warfarin.
5)Active, clinically significant medical or psychiatric conditions that would interfere with study participation, at the discretion of the site investigator or designee.
6)Prior enrollment in The dPEP Kenya Study

Study & Design

• Study Type: Interventional
• Study Design: Not specified